Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma Inc (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company pioneering novel CAR-T therapies and Tissue-Specific Therapeutics™ for hematologic cancers and autoimmune disorders. This page serves as the definitive source for verified corporate announcements, clinical development updates, and regulatory milestones.
Investors and researchers will find chronologically organized press releases detailing clinical trial results, FDA designations, and strategic partnerships. Our collection includes updates on lead candidates like NXC-201 for AL Amyloidosis and IMX-110 for soft tissue sarcoma, featuring their unique Single-Day CRS profiles and TME Normalization Technology advancements.
All content is curated to provide stakeholders with essential insights into the company’s progress in addressing unmet medical needs through innovative cell therapies. Regular updates ensure access to the latest information on trial phases, scientific publications, and intellectual property developments.
Bookmark this page for streamlined tracking of Immix Biopharma’s advancements in next-generation immunotherapy and biopharmaceutical research.
Nexcella, a subsidiary of Immix Biopharma (NASDAQ: IMMX), reported promising clinical data from its Phase 1b/2 NEXICART-1 trial (NCT04720313) for NXC-201, a CAR-T therapy targeting relapsed/refractory multiple myeloma and AL amyloidosis. The data indicated a 92% overall response rate in multiple myeloma and a 100% response rate in AL amyloidosis patients, with median progression-free survival of 12.3 months. These results were presented at the EBMT 49th Annual Meeting in Paris. Nexcella aims to submit a BLA for FDA approval in both conditions after treating 100 patients for multiple myeloma and 30-40 for AL amyloidosis. The markets for multiple myeloma and AL amyloidosis are projected to expand significantly by 2027 and 2025, respectively, presenting substantial commercial opportunities for NXC-201.
Nexcella Inc., a subsidiary of Immix Biopharma (NASDAQ: IMMX), announced the presentation of updated clinical data for NXC-201, a CAR-T therapy for multiple myeloma and AL amyloidosis, at the 49th annual meeting of the European Society for Blood and Marrow Transplantation in Paris from April 23-26, 2023.
The updated data show a 90% overall response rate and a 59% complete response rate in relapsed/refractory multiple myeloma. Notably, NXC-201 achieved a 100% hematologic and organ response rate in AL amyloidosis patients. These results reflect the potential of NXC-201 as the first outpatient CAR-T therapy for these conditions.
Nexcella, a subsidiary of Immix Biopharma, Inc. (NASDAQ: IMMX), announced the publication of an editorial in Haematologica discussing the safety and efficacy of their BCMA CAR-T cell therapy, NXC-201. The therapy shows a 75% overall response rate, comparable to existing FDA-approved therapies. As of March 2023, 58 patients have been treated, primarily for multiple myeloma. The multiple myeloma market, valued at $13.9 billion in 2017, is projected to reach $28.7 billion by 2027. NXC-201 is under investigation for relapsed or refractory multiple myeloma and AL amyloidosis, demonstrating a favorable safety profile with outpatient treatment potential.
Nexcella, a subsidiary of Immix Biopharma (IMMX), announced promising results for NXC-201, a CAR-T therapy targeting relapsed/refractory multiple myeloma and AL amyloidosis. The treatment has shown a 100% complete hematologic response and a 100% organ response rate in 8 AL amyloidosis patients. A total of 58 patients have been treated, with notable safety data confirming outpatient treatment potential. The $13.9 billion multiple myeloma market is projected to grow to $28.7 billion by 2027, while the amyloidosis market is expected to reach $6 billion by 2025, according to industry research.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced on March 10, 2023, that it has no exposure to Silicon Valley Bank or Silvergate Bank. This statement underscores the company’s financial stability amidst recent banking sector concerns. ImmixBio is a clinical-stage biopharmaceutical company focusing on Tissue-Specific Therapeutics (TSTx)™ aimed at treating oncology and immuno-dysregulated diseases. With its proprietary SMARxT Tissue-Specific™ Platform, ImmixBio is innovating in the treatment landscape by targeting tumor microenvironments to enhance therapeutic efficacy.
Immix Biopharma, Inc. (Nasdaq: IMMX) announced a discussion on positive clinical data for its CAR-T therapy, NXC-201, targeting AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14, 2023. NXC-201 has shown promising results in recent trials, achieving a 90% overall response rate in relapsed/refractory multiple myeloma patients and a 100% organ response rate in AL amyloidosis patients. The recommended Phase 2 dose for both conditions is set at 800 million CAR+T cells. These results position NXC-201 as a significant player in the treatment landscape for these diseases.
Nexcella, a subsidiary of Immix Biopharma (NASDAQ: IMMX), announced the successful dosing of 50 patients with its CAR-T therapy NXC-201 in an ongoing Phase 1b/2a trial targeting relapsed/refractory multiple myeloma and AL amyloidosis. Enrollment continues robustly at 5 patients monthly, with a goal of 100 total patients for U.S. FDA BLA approval. Nexcella plans to present data from this 50-patient cohort later this year at a scientific forum. The therapy demonstrated a 90% overall response rate in multiple myeloma cases, highlighting its potential as an outpatient treatment with reduced toxicity, enhancing its market competitiveness in effective cancer therapies.
FAQ
What is the current stock price of Immix Biopharma (IMMX)?
What is the market cap of Immix Biopharma (IMMX)?
